Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
复制标题
DOI：
10.1016/j.ophtha.2021.04.017
复制
发表时间：
2021-12
期刊：
影响因子：
13.7
通讯作者：
Acharya NR
中科院分区：
文献类型：
--
作者：
Lu A;Sun Y;Porco TC;Arnold BF;Acharya NR
研究重组带状疱疹疫苗在美国普通人群中预防眼部带状疱疹的有效性。回顾性、观察性队列研究。2018年至2019年入组OptumLabs®数据仓库（OLDW）（OptumLabs，剑桥，MA）且年龄符合带状疱疹疫苗接种条件（≥50岁）的个人。OLDW是一个纵向的、去识别的管理索赔和电子健康记录数据库，数据库中的美国商业保险、Medicare Part D或Medicare Advantage患者需要连续入组≥365天才有资格。排除了在研究入选前一年内诊断为带状疱疹或免疫功能低下的患者。用CPT编码确定重组带状疱疹疫苗接种情况，用ICD-10编码确定眼带状疱疹。考克斯比例风险回归模型用于估计与RZV相关的HZO的风险比，逆概率加权用于控制混杂因素。疫苗有效性是根据风险比计算的。评估了接种疫苗与未接种疫苗的人-时间和疫苗有效性中带状疱疹眼的发生率。从2018年1月1日至2019年12月31日，共有4，842，579人参与了这项研究。177 289人（3.7%）接受了两次有效剂量的RZV。接种组带状疱疹眼的发病率为25.5例（95% CI：17.4，35.8）/100 000人-年，而未接种组为76.7例（95% CI：74.7，78.7）。RZV治疗带状疱疹眼的总校正有效率为89.1%（95%CI：82.9，93.0）。在现实世界中，RZV对50岁及以上个体带状疱疹眼的有效性很高。但是，这项研究中的低疫苗接种率凸显了公共卫生需要增加带状疱疹疫苗接种。眼科医生可以在向符合条件的患者推荐疫苗接种方面发挥重要作用。
To examine the effectiveness of the recombinant zoster vaccine for preventing herpes zoster ophthalmicus in the general US population. Retrospective, observational cohort study. Individuals enrolled in the OptumLabs® Data Warehouse (OLDW) (OptumLabs, Cambridge, MA) who were age-eligible for herpes zoster vaccination (≥50 years old) from 2018 through 2019. OLDW is a longitudinal, de-identified administrative claims and electronic health record database of patients in the United States with commercial insurance, Medicare Part D or Medicare Advantage Patients were required to have ≥365 days of continuous enrollment to be eligible. Those with a diagnosis code of herpes zoster or an immunocompromising condition within one year prior to study inclusion were excluded. Vaccination with the recombinant zoster vaccine was ascertained by CPT codes, and herpes zoster ophthalmicus was ascertained by ICD-10 codes. Cox proportional hazards regression models were used to estimate the hazard ratio of HZO associated with RZV, and inverse-probability weighting was used to control for confounding. Vaccine effectiveness was calculated from hazard ratios. Incidence of herpes zoster ophthalmicus in vaccinated vs. unvaccinated person-time and vaccine effectiveness were assessed. From January 1, 2018 to December 31, 2019 a total of 4 842 579 individuals were included in this study. 177 289 (3.7%) received two valid doses of RZV. The incidence rate of herpes zoster ophthalmicus was 25.5 (95% CI: 17.4, 35.8) cases per 100 000 person-years in the vaccinated group compared to 76.7 (95% CI: 74.7, 78.7) in the unvaccinated group. The overall adjusted effectiveness of RZV against herpes zoster ophthalmicus was 89.1% (95% CI: 82.9, 93.0). The effectiveness of RZV against herpes zoster ophthalmicus in individuals ages 50 years old and above is high in a real-world setting. However, the low vaccination rate in this study highlights the public health need to increase herpes zoster vaccination. Ophthalmologists can play an important role in recommending vaccination to eligible patients.
登录
查看更多内容
DOI：
10.1056/nejmcp1302674
发表时间：
2013-07-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
Cohen JI
通讯作者：
Cohen JI
影响因子：
2
作者：
Austin PC
通讯作者：
Austin PC
影响因子：
2.9
作者：
Kawai K;Gebremeskel BG;Acosta CJ
通讯作者：
Acosta CJ
影响因子：
13.7
作者：
Kong, Christina L.;Thompson, Ryan R.;Acharya, Nisha R.
通讯作者：
Acharya, Nisha R.
影响因子：
5
作者：
Baxter, Roger;Bartlett, Joan;Saddier, Patricia
通讯作者：
Saddier, Patricia